share_log

JP Morgan Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $74

Benzinga ·  Mar 6 19:38

JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target from $73 to $74.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment